Oculis Holding AG (OCS) Total Non-Current Liabilities (2021 - 2026)
Oculis Holding AG (OCS) posted quarterly Total Non-Current Liabilities of $4.4 million for Q1 2026, up 91.01% year-over-year from $2.3 million in Q1 2025, and up 12.97% quarter-over-quarter from $3.9 million in Q4 2025.
Oculis Holding AG (OCS) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Oculis Holding AG's Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $4.4 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 91.01% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $4.4 million (up 91.01% YoY), while the FY2025 annual figure was $3.8 million, up 22.05% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $4.4 million, up from $3.9 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $127.7 million in Q4 2022, with the low at $938676.2 in Q2 2023.
- The 5-year median for Total Non-Current Liabilities is $2.5 million (2024), against an average of $12.3 million.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities slumped 98.64% in 2023, then jumped 167.65% in 2024.
- Oculis Holding AG's Total Non-Current Liabilities stood at $127.7 million in 2022, then plunged by 98.64% to $1.7 million in 2023, then jumped by 80.18% to $3.1 million in 2024, then grew by 26.08% to $3.9 million in 2025, then grew by 12.97% to $4.4 million in 2026.
- Business Quant data shows OCS's Total Non-Current Liabilities at $4.4 million in Q1 2026, $3.9 million in Q4 2025, and $4.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | 3.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.89 Mn |
| Mar 31, 2026 | 4.45 Mn |
| Dec 31, 2025 | 3.94 Mn |
| Sep 30, 2025 | 4.39 Mn |
| Jun 30, 2025 | 2.39 Mn |
| Mar 31, 2025 | 2.33 Mn |
| Dec 31, 2024 | 3.12 Mn |
| Sep 30, 2024 | 3.07 Mn |
| Jun 30, 2024 | 2.51 Mn |
| Mar 31, 2024 | 1.75 Mn |
| Dec 31, 2023 | 1.73 Mn |
| Sep 30, 2023 | 1.34 Mn |
| Jun 30, 2023 | 938,676.16 |
| Dec 31, 2022 | 127.71 Mn |
| Dec 31, 2021 | 124.65 Mn |